MiRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2569-2580

  Zhao, Gang ^a   Wang, Bo ^a   Liu, Yang ^a   Zhang, Jun Gang ^a   Deng, Shi Chang ^a   Qin, Qi ^a   Tian, Kui ^a   Li, Xiang ^a   Zhu, Shuai ^a   Niu, Yi ^a   Gong, Yi Iong ^a   Wang, Chun You ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 141; MITOGEN ACTIVATED PROTEIN KINASE 4;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ADULT; AGED; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, NUDE; MICRORNAS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887486620     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0296     Document Type: Article

References (39)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
2. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009;11:228-34.
3. Xu P, Vernooy SY, Guo M, Hay BA. The drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol 2003;13:790-5.
4. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993;75:855-62.
5. Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in drosophila. Cell 2003;113:25-36.
6. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-54.
7. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
8. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8.
9. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363:1049-57.
10. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 2010;5:e10630.
11. Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 2000;95:17-31.
12. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial- mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 andZEB2. J Biol Chem 2008;283:14910-4.
13. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007; 67:7972-6.
14. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR- 200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9:582-9.
15. Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA, et al. Upregulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009;69:6704-12.
16. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
17. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem 2011;286:25992-6002.
18. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11:1487-95.
19. Hu W, Wang X, Ding X, Li Y, Zhang X, Xie P, et al. MicroRNA-141 Represses HBV Replication by Targeting PPARA. PLoS ONE 2012;7: e34165 .
20. Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011;17:1627-35.
21. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 2011;6:e17745.
22. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR- 200c. J Pathol 2008;216:418-27.
23. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009;138:592-603.
24. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007;26:4442-52.
25. Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T, et al. Down-regulation of miR- 141 in gastric cancer and its involvement in cell growth. J Gastroenterol 2009;44:556-61.
26. Hu Y, Leo C, Yu S, Huang B, Wang H, Shen M, et al. Identification and functional characterization of a novel human misshapen/Nck interacting kinase-related kinase, hMINKb. J Biol Chem 2004;279:54387-97.
27. Zohn IE, Li Y, Skolnik EY, Anderson KV, Han J, Niswander L. p38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. Cell 2006;125:957-69.
28. Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, et al. Asmall interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad SciUS A 2006;103: 3775-80.
29. Bouzakri K, Zierath JR. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-a-induced insulin resistance. J Biol Chem 2007;282:7783-9.
30. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009;458:1180-4.
31. Wright JH, Wang X, Manning G, LaMere BJ, Le P, Zhu S, et al. The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol 2003;23:2068-82.
32. Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, et al. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 2011;17:710-20.
33. Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, et al.Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res 2008;14:7043-9.
34. Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, et al. Nuclear factor-kBactivation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 2005;11:2518-25.
35. Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, et al. Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. Pathol Res Pract 2012;208:541-8.
36. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A 1992;89: 5645-9.
37. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343-59.
38. Katz M, Takimoto S, Spivac D, Moossa AR, Hoffman RM, Bouvet M. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res 2003; 113:151-60.
39. Tran Cao HS, Kaushal S, Lee C, Snyder CS, Thompson KJ, Horgan S, et al. Fluorescence laparoscopy imaging of pancreatic tumor progression in an orthotopic mouse model. Surg Endosc 2011;25:48-54.